Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.65 |
| ▸ | ALPL | P05186 | 1/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | AHR | P35869 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663611 | 0.92 | NPC1 (0.89) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL6562826 | 0.91 | NPC1 (1.00) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL7514363 | 0.85 | NPC1 (0.78) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL6565951 | 0.82 | ALPL (0.76) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL29466507 | 0.81 | MEN1 (0.78) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL1665225 | 0.80 | RAB9A (0.69) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL6585868 | 0.79 | NPY5R (1.00) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL1664228 | 0.79 | RAB9A (0.68) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL4264906 | 0.78 | ALPL (0.78) | NPC1RAB9AMAPTNPY5RALPL | |
| SCHEMBL6583864 | 0.77 | NPY5R (0.87) | NPC1RAB9AMAPTNPY5RALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307519-A1 | SMALL MOLECULES FOR RESTORING FUNCTION TO P53 CANCER MUTANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307519-A1 | SMALL MOLECULES FOR RESTORING FUNCTION TO P53 CANCER MUTANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-29 | — | — | US | disclosed |
| EP-0788358-B1 | USE OF PYRAZOLE COMPOUNDS FOR THE TREATMENT OF GLOMERULONEPHRITIS, CANCER, ATHEROSCLEROSIS OR RESTENOSIS | MILLENNIUM PHARM INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-5916908-A | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases | COR THERAPEUTICS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0788358-A2 | PHARMACEUTICAL PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | COR THERAPEUTICS, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996014843-A2 | PHARMACEUTICAL PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | COR THERAPEUTICS, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307519-A1 | SMALL MOLECULES FOR RESTORING FUNCTION TO P53 CANCER MUTANTS | TP53, TP53BP1, KRAS | NPC1 4019/4885RAB9A 1488/4885MAPT 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.